Skip to main content
Premium Trial:

Request an Annual Quote

Waters Shares Spike 14 Percent on Strong Q4 Earnings

NEW YORK, Jan.24 (GenomeWeb News) - Waters shares rallied as much as 14 percent in Tuesday trade after the company reported a growth of 7 percent in fourth-quarter organic sales.


The stock was trading up $5.24 or 13.88 percent, at $43 in afternoon trade.


As GenomeWeb News reported earlier this morning, Waters posted fourth-quarter sales growth of 3 percent on strong growth in its chromatography business and sales in Asia.


Total sales for the three months ended Dec. 31 increased to $332 million from $324 million one year ago. Eliminating the effects of foreign currency, sales grew by 7 percent, the company said.


R&D spending in the period increased slightly to $16.7 million from $16.5 million year over year.


Waters' net income increased to $78.2 million, or $0.72 per basic share, from $71.5 million, or $0.59 per basic share in the year-ago period.


CEO and President Douglas Berthiaume said the revenue and profit "exceeded our expectations."


As of Jan. 1, Waters had approximately $494 million in cash and equivalents on hand.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.